Eduard Stange

Prof. Dr. Eduard Stange

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JWJan Wehkamp
Jan Wehkamp
NSNita H. Salzman
Nita H. Salzman
EPEdith Porter
Edith Porter
SNSabine Nuding
Sabine Nuding
MWMichael Weichenthal
Michael Weichenthal
CBCharles Bevins
Charles Bevins
The pathogenesis of Crohn′s disease (CD), an idiopathic inflammatory bowel disease, is attributed, in part, to intestinal bacteria that may initiate and perpetuate mucosal inflammation in genetically susceptible individuals. Paneth cells (PC) are the major source of antimicrobial peptides in the small intestine, including human α-defensins HD5 and HD6. We tested the hypothesis that reduced expression of PC α-defensins compromises mucosal host defenses and predisposes patients to CD of the ileum. We report that patients with CD of the ileum have reduced antibacterial activity in their intestinal mucosal extracts. These specimens also showed decreased expression of PC α-defensins, whereas the expression of eight other PC products either remained unchanged or increased when compared with controls. The specific decrease of α-defensins was independent of the degree of inflammation in the specimens and was not observed in either CD of the colon, ulcerative colitis, or pouchitis. The functional consequence of α-defensin expression levels was examined by using a transgenic mouse model, where we found changes in HD5 expression levels, comparable to those observed in CD, had a pronounced impact on the luminal microbiota. Thus, the specific deficiency of PC defensins that characterizes ileal CD may compromise innate immune defenses of the ileal mucosa and initiate and/or perpetuate this disease.

11 October 2004 in Gut
Verified
Journal Article
Open access
PDF file
JWJ Wehkamp
J Wehkamp
JHJ Harder
J Harder
MWM Weichenthal
M Weichenthal
Matthias SchwabMatthias Schwab
Matthias Schwab
ESE Schäffeler
E Schäffeler
ESEduard Stange
Eduard Stange
Background: Mutations in NOD2, a putative intracellular receptor for bacterial peptidoglycans, are associated with a subset of Crohn’s disease but the molecular mechanism linking this protein with the disease pathogenesis remains unclear. Human α defensins (HD-5 and HD-6) are antibiotic effector molecules predominantly expressed in Paneth cells of the ileum. Paneth cells also express NOD2. To address the hypothesis that the function of NOD2 may affect expression of Paneth cell defensins, we compared their expression levels with respect to NOD2 mutations in Crohn’s disease. Methods: Forty five Crohn’s disease patients (24 with NOD2 mutations, 21 with wild-type NOD2) and 12 controls were studied. Real time reverse transcription-polymerase chain reaction was performed with mucosal mRNA for HD-5, HD-6, lysozyme, secretory phospholipase A 2 (sPLA 2 ), tumour necrosis factor α, interleukin 8, and human hypoxanthine phosphoribosyltransferase (housekeeping gene). Immunohistochemistry with anti-HD-5 and histological Paneth cell staining were performed in 10 patients with NOD2 mutations or wild-type genotypes. Results: Ileal expression of HD-5 and HD-6, but not sPLA 2 or lysozyme, were diminished in affected ileum, and the decrease was significantly more pronounced in patients with NOD2 mutations. In the colon, HD-5, HD-6, and sPLA 2 were increased during inflammation in wild-type but not in NOD2 mutated patients. In both the colon and ileum, proinflammatory cytokines and lysozyme were unaffected by NOD2 status. Immunohistochemistry identified Paneth cells as the sole source of HD-5. Conclusion: As alpha defensins are important in the mucosal antibacterial barrier, their diminished expression may explain, in part, the bacterial induced mucosal inflammation and ileal involvement of Crohn’s disease, especially in the case of NOD2 mutations.

15 February 2006 in Gut
Verified
Journal Article
Open access
PDF file
STS P L Travis
S P L Travis
ESEduard Stange
Eduard Stange
MLM Lémann
M Lémann
TÖT Öresland
T Öresland
YCY Chowers
Y Chowers
NMN J Mortensen
N J Mortensen
This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohn’s disease. The third section on special situations in Crohn’s disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohn’s disease.

1 March 2008 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
ESEduard Stange
Eduard Stange
STS.P.L. Travis
S.P.L. Travis
SVSeverine Vermeire
Severine Vermeire
WRW. Reinisch
W. Reinisch
KGK. Geboes
K. Geboes
BWB.F. Warren
B.F. Warren

15 February 2006 in Gut
Verified
Journal Article
Open access
PDF file
ESEduard Stange
Eduard Stange
STS P L Travis
S P L Travis
SVSeverine Vermeire
Severine Vermeire
CBC Beglinger
C Beglinger
LKL Kupcinkas
L Kupcinkas
WRW Reinisch
W Reinisch
The consensus endeavours to address these differences. The consensus is not meant to supersede the guidelines of different countries (such as those from the UK,2 Germany,3 or France), which reach broadly the same conclusions as they are, after all, based on the same evidence. Rather, the aim of the consensus is to promote a European perspective on the management of CD and its dilemmas. As the development of guidelines is an expensive and time consuming process, it may help to avoid duplication of effort in the future. A consensus is also considered important because an increasing number of therapeutic trials are based in Europe, especially in eastern European countries where practice guidelines have yet to be published.

3 October 2019 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Open access
ESEduard Stange
Eduard Stange
BSBjoern O. Schroeder
Bjoern O. Schroeder
Introduction: Inflammatory bowel diseases (IBD) are on the rise worldwide. This review covers the current concepts of the etiology of Crohn´s disease and ulcerative colitis by focusing on an unbalanced interaction between the intestinal microbiota and the mucosal barrier. Understanding these issues is of paramount importance for the development of targeted therapies aiming at the disease cause. Area covered: Gut microbiota alterations and a dysfunctional intestinal mucosa are associated with IBD. Here we focus on specific defense structures of the mucosal barrier, namely antimicrobial peptides and the mucus layer, which keep the gut microbiota at a distance under healthy conditions and are defective in IBD. Expert commentary: The microbiology of both forms of IBD is different but characterized by a reduced bacterial diversity and richness. Abundance of certain bacterial species is altered, and the compositional changes are related to disease activity. In IBD the mucus layer above the epithelium is contaminated by bacteria and the immune reaction is dominated by the antibacterial response. Human genetics suggest that many of the basic deficiencies in the mucosal response, due to Paneth cell, defensin and mucus defects, are primary. Nutrition may also be important but so far there is no therapy targeting the mucosal barrier.